Data from phase 2 study of Progenics' PSMA-targeted imaging agent 1404 published
Progenics announced the publication of previously-reported results from the Phase 2 study of 1404 in the online edition of the Journal of Nuclear Medicine. 1404 is a PSMA-targeted small molecule SPECT/CT imaging agent that is designed to visualize prostate cancer. March 24, 2017